Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
19.50B
Market cap19.50B
Price-Earnings ratio
13.97
Price-Earnings ratio13.97
Dividend yield
Dividend yield
Average volume
1.26M
Average volume1.26M
High today
High today
Low today
Low today
Open price
$99.14
Open price$99.14
Volume
0.00
Volume0.00
52 Week high
$112.29
52 Week high$112.29
52 Week low
$61.11
52 Week low$61.11

Stock Snapshot

The current Incyte(INCY) stock price is $97.63, with a market capitalization of 19.5B. The stock trades at a price-to-earnings (P/E) ratio of 13.97.

On 2026-05-15, Incyte(INCY) stock opened at $99.14, reached a high of —, and a low of —.

The Incyte(INCY)'s current trading volume is 0, compared to an average daily volume of 1.26M.

During the past year, Incyte(INCY) stock moved between $61.11 at its lowest and $112.29 at its peak.

During the past year, Incyte(INCY) stock moved between $61.11 at its lowest and $112.29 at its peak.

INCY News

Simply Wall St 5d
Impressive Earnings May Not Tell The Whole Story For Incyte

Incyte Corporation ( ) announced strong profits, but the stock was stagnant. We did some digging, and we found some concerning factors in the details. Advertis...

Impressive Earnings May Not Tell The Whole Story For Incyte
Simply Wall St 7d
Assessing Incyte Valuation After FDA Wins For Jakafi XR Opzelura And Pancreatic Cancer Therapy

Incyte (INCY) stock is in focus after the US FDA approved once daily Jakafi XR, along with positive Phase 3 Opzelura data in atopic dermatitis and orphan drug d...

Assessing Incyte Valuation After FDA Wins For Jakafi XR Opzelura And Pancreatic Cancer Therapy
TipRanks 7d
Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial

Incyte (INCY) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Di...

Analyst ratings

52%

of 29 ratings
Buy
37.9%
Hold
51.7%
Sell
10.3%

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.